Hederagenin Improves Adriamycin-induced Nephropathy by Inhibiting the JAK/STAT Signaling Pathway
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2024/04/23
-
Indian UGC (journal)
-
Refrences44
-
Xia Zhong
-
Jian Jia
-
Ruizhi Tan
-
Li Wang ORCID (unauthenticated)
Abstract
Cite
Zhong, Xia, et al. “Hederagenin Improves Adriamycin-Induced Nephropathy by Inhibiting the JAK STAT Signaling Pathway”. Integrative Medicine in Nephrology and Andrology, vol. 11, no. 2, 2024, https://doi.org/10.1097/imna-d-22-00016.
Zhong, X., Jia, J., Tan, R., & Wang, L. (2024). Hederagenin Improves Adriamycin-induced Nephropathy by Inhibiting the JAK/STAT Signaling Pathway. Integrative Medicine in Nephrology and Andrology, 11(2). https://doi.org/10.1097/imna-d-22-00016
Zhong, Xia, Jian Jia, Ruizhi Tan, and Li Wang. “Hederagenin Improves Adriamycin-Induced Nephropathy by Inhibiting the JAK STAT Signaling Pathway”. Integrative Medicine in Nephrology and Andrology 11, no. 2 (2024). https://doi.org/10.1097/imna-d-22-00016.
Zhong X, Jia J, Tan R, Wang L. Hederagenin Improves Adriamycin-induced Nephropathy by Inhibiting the JAK/STAT Signaling Pathway. Integrative Medicine in Nephrology and Andrology. 2024;11(2).
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer | Signal Transduction and Targeted Therapy |
| 39 | 2023 |
| Quantification of Glomerular Structural Lesions: Associations With Clinical Outcomes and Transcriptomic Profiles in Nephrotic Syndrome | American Journal of Kidney Diseases |
| 13 | 2022 |
| The protective effect of hederagenin on renal fibrosis by targeting muscarinic acetylcholine receptor | Bioengineered |
| 9 | 2022 |
Podocyte Sphingolipid Signaling in Nephrotic Syndrome. | Cellular Physiology and Biochemistry |
| 8 | 2021 |
Luteolin as a modulator of skin aging and inflammation | BioFactors |
| 133 | 2021 |
Refrences Analysis
The category
Medicine: Medicine (General) 15
is the most frequently represented among the references in this article. It primarily includes studies from International Immunopharmacology and Pediatric Clinics of North America. The chart below illustrates the number of referenced publications per year.